Pfizer Cost of Goods Sold 2010-2024 | PFE
Pfizer annual/quarterly cost of goods sold history and growth rate from 2010 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
- Pfizer cost of goods sold for the quarter ending June 30, 2024 was $3.300B, a 1.95% increase year-over-year.
- Pfizer cost of goods sold for the twelve months ending June 30, 2024 was $23.510B, a 1.36% decline year-over-year.
- Pfizer annual cost of goods sold for 2023 was $24.954B, a 27.34% decline from 2022.
- Pfizer annual cost of goods sold for 2022 was $34.344B, a 11.43% increase from 2021.
- Pfizer annual cost of goods sold for 2021 was $30.821B, a 263.28% increase from 2020.
Pfizer Annual Cost of Goods Sold
(Millions of US $) |
| 2023 |
$24,954 |
| 2022 |
$34,344 |
| 2021 |
$30,821 |
| 2020 |
$8,484 |
| 2019 |
$8,054 |
| 2018 |
$8,987 |
| 2017 |
$11,228 |
| 2016 |
$12,322 |
| 2015 |
$9,648 |
| 2014 |
$9,577 |
| 2013 |
$9,586 |
| 2012 |
$9,821 |
| 2011 |
$12,500 |
| 2010 |
$14,788 |
| 2009 |
$8,459 |
Pfizer Quarterly Cost of Goods Sold
(Millions of US $) |
| 2024-06-30 |
$3,300 |
| 2024-03-31 |
$3,379 |
| 2023-12-31 |
$7,562 |
| 2023-09-30 |
$9,269 |
| 2023-06-30 |
$3,237 |
| 2023-03-31 |
$4,886 |
| 2022-12-31 |
$9,649 |
| 2022-09-30 |
$6,063 |
| 2022-06-30 |
$8,648 |
| 2022-03-31 |
$9,984 |
| 2021-12-31 |
$9,736 |
| 2021-09-30 |
$9,932 |
| 2021-06-30 |
$6,996 |
| 2021-03-31 |
$4,157 |
| 2020-12-31 |
$2,711 |
| 2020-09-30 |
$2,007 |
| 2020-06-30 |
$1,826 |
| 2020-03-31 |
$1,940 |
| 2019-12-31 |
$443 |
| 2019-09-30 |
$2,602 |
| 2019-06-30 |
$2,576 |
| 2019-03-31 |
$2,433 |
| 2018-12-31 |
$814 |
| 2018-09-30 |
$2,694 |
| 2018-06-30 |
$2,916 |
| 2018-03-31 |
$2,563 |
| 2017-12-31 |
$3,256 |
| 2017-09-30 |
$2,844 |
| 2017-06-30 |
$2,660 |
| 2017-03-31 |
$2,468 |
| 2016-12-31 |
$3,212 |
| 2016-09-30 |
$3,085 |
| 2016-06-30 |
$3,174 |
| 2016-03-31 |
$2,851 |
| 2015-12-31 |
$3,411 |
| 2015-09-30 |
$2,219 |
| 2015-06-30 |
$2,180 |
| 2015-03-31 |
$1,838 |
| 2014-12-31 |
$2,702 |
| 2014-09-30 |
$2,368 |
| 2014-06-30 |
$2,462 |
| 2014-03-31 |
$2,045 |
| 2013-12-31 |
$2,794 |
| 2013-09-30 |
$2,287 |
| 2013-06-30 |
$2,242 |
| 2013-03-31 |
$2,263 |
| 2012-12-31 |
$2,391 |
| 2012-09-30 |
$2,309 |
| 2012-06-30 |
$2,376 |
| 2012-03-31 |
$2,745 |
| 2011-12-31 |
$1,827 |
| 2011-09-30 |
$3,409 |
| 2011-06-30 |
$3,571 |
| 2011-03-31 |
$3,693 |
| 2010-12-31 |
$3,112 |
| 2010-09-30 |
$3,790 |
| 2010-06-30 |
$3,684 |
| 2010-03-31 |
$4,202 |
| 2009-12-31 |
$3,506 |
| 2009-09-30 |
$1,789 |
| 2009-06-30 |
$1,756 |
| 2009-03-31 |
$1,408 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$168.584B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
